Lidorestat

Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC50 of 5 nM. Lidorestat can be used for chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation[1][2][3].

Product Specifications

CAS Number

[245116-90-9]

Product Name Alternative

IDD-676

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Aldose Reductase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/lidorestat.html

Purity

99.50

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

OC(CN1C(C=CC=C2)=C2C(CC3=NC(C(F)=C(F)C=C4F)=C4S3)=C1)=O

Molecular Formula

C18H11F3N2O2S

Molecular Weight

376.35

Precautions

H302, H315, H319, H335

References & Citations

[1]Noh HL, et al. Regulation of plasma fructose and mortality in mice by the aldose reductase inhibitor lidorestat. J Pharmacol Exp Ther. 2009 Feb;328 (2) :496-503.|[2]Van Zandt MC, et al. Discovery of 3-[ (4,5,7-trifluorobenzothiazol-2-yl) methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. J Med Chem. 2005 May 5;48 (9) :3141-52.|[3]Maccari R, et al. Identification of new non-carboxylic acid containing inhibitors of aldose reductase. Bioorg Med Chem. 2010 Jun 1;18 (11) :4049-55.